Irritable Bowel Syndrome: Phenotype-Directed Pharmacotherapy

Make a Positive Diagnosis Without Ignoring Red Flags

Assess abdominal pain chronology, stool frequency and form, bloating, dietary and psychosocial triggers, medication exposure, and impact on functioning. Distinguish IBS-C (constipation predominant), IBS-D (diarrhea predominant), IBS-M (mixed), and unclassified patterns using stool form history. Rectal bleeding, anemia, unintentional weight loss, fever, significant nocturnal diarrhea, new-onset symptoms in an older adult, and family history of colorectal cancer or IBD warrant investigation. Celiac testing and inflammatory biomarkers/stool testing are useful selectively, particularly in IBS-D when the differential includes inflammatory disease (Lacy et al., 2021; Poole, 2026).

Treatment goals include relief of global symptom burden, fewer pain episodes, more predictable bowel habits and improved quality of life. Review soluble fiber, structured diet trials, targeted low-FODMAP intervention with dietitian support, sleep, exercise, and brain-gut behavioral strategies. Do not impose indefinite restrictive diets without reintroduction or nutritional oversight (Chey et al., 2022; Poole, 2026).

IBS-C: Bowel Regularity Is Not the Same as Pain Control

Treatment	Place in IBS-C	Clinical distinction / safety
Psyllium and other soluble fiber	Reasonable early treatment, introduced gradually.	May improve stool form and global symptoms; bloating can increase with rapid titration.
Polyethylene glycol	Relieves hard stools and infrequent defecation.	Often improves stool output more than abdominal pain or overall IBS burden.
Linaclotide	AGA strong recommendation in IBS-C; adult labeled regimen 290 mcg orally once daily.	May improve pain and stool frequency; diarrhea and dehydration limit use. Pediatric indications differ by age and diagnosis.
Plecanatide	Conditional recommendation; adult IBS-C dose 3 mg orally once daily.	Monitor severe diarrhea and contraindications related to pediatric use or obstruction.
Tenapanor	Conditional recommendation; adult IBS-C dose 50 mg orally twice daily before meals.	Sodium/hydrogen exchanger inhibition; diarrhea can be treatment-limiting.
Lubiprostone	Conditional recommendation; adult IBS-C dose 8 mcg orally twice daily in eligible women.	Nausea is a frequent limitation; verify current label population and pregnancy considerations.

The AGA 2022 IBS-C guideline strongly recommends linaclotide and conditionally recommends tenapanor, plecanatide, lubiprostone, and PEG. The May 2026 Linzess label specifies IBS-C treatment at age 7 years or older (145 mcg daily) and pediatric functional constipation at age 2 years or older (72 mcg daily). Adult IBS-C uses 290 mcg daily. Linaclotide is contraindicated below age 2 because of serious dehydration risk. Product labels should be checked before presenting pediatric treatment (Allergan, Inc., 2026; Chang et al., 2022).

IBS-D: Treat Stool Urgency and Visceral Pain Without Confusing It With Infection

Option	Clinical role	Selection and exclusions
Loperamide	May reduce diarrhea and improve stool consistency; an urgency benefit is not established.	Evidence for global IBS symptom relief is limited; do not use to mask fever or bloody inflammatory diarrhea.
Rifaximin	Selected IBS-D patients with ongoing global symptoms or bloating: adult 550 mg orally three times daily for 14 days.	For initial responders who relapse, the regimen may be repeated up to two times; screen for infection and relevant contraindications.
Eluxadoline	Selected adult IBS-D; slows intestinal transit via opioid receptor actions.	Contraindicated without a gallbladder and in important pancreatic, biliary, hepatic and alcohol-related risk settings.
Alosetron	Restricted to women with severe diarrhea-predominant IBS who have not responded adequately to conventional therapy.	Boxed warning: ischemic colitis and serious complications of constipation. Discontinue immediately for constipation or symptoms of ischemic colitis, including rectal bleeding, bloody diarrhea, or new or worsening abdominal pain; do not resume after ischemic colitis (Legacy Pharma USA Inc., 2026).
Tricyclic antidepressant	Neuromodulator for pain-predominant IBS.	A low-dose tricyclic may benefit global IBS symptoms; assess constipation burden and the selected agent’s anticholinergic, QT, and sedative risks before use.

The AGA 2022 IBS-D guideline conditionally supports rifaximin, retreatment in prior responders, eluxadoline, alosetron, loperamide, and tricyclic antidepressants. It does not imply equal efficacy for pain, stool consistency, or whole-syndrome outcomes. Drug selection should reflect the patient’s dominant symptom and risk factors (Lembo et al., 2022).

IBS-D Prescribing: Two Agents With Noninterchangeable Restrictions

Medication	FDA-label dosing	Contraindication / treatment gate
Rifaximin (Xifaxan)	550 mg orally three times daily for 14 days; previous responders who relapse may repeat the same course up to two times.	Not the 200-mg traveler’s diarrhea regimen; assess infection symptoms and medication interactions, especially severe hepatic impairment and P-gp inhibitors.
Eluxadoline (Viberzi)	100 mg orally twice daily with food; 75 mg twice daily for listed patient groups, including mild/moderate hepatic impairment, reduced renal function, OATP1B1 inhibitor use or intolerance.	Absolutely contraindicated without a gallbladder, in prior pancreatitis, biliary obstruction/sphincter of Oddi dysfunction, heavy alcohol use, severe hepatic impairment and severe constipation/obstruction. Watch early pancreatitis.
Plecanatide (IBS-C comparison)	3 mg orally once daily in adults.	Contraindicated under 6 years; avoid from age 6 to under 18. Pediatric linaclotide approval does NOT extend to plecanatide.

Prescribing-label source note: Consult the indication-specific U.S. product labels cited in the references (Allergan, Inc., 2024; Salix Pharmaceuticals, Inc., 2024; Salix Pharmaceuticals, Inc., 2025); verify the current formulation, dose, warnings and population before use.

A patient with IBS-D who underwent cholecystectomy is not an eluxadoline candidate even if diarrhea is severe; postmarketing pancreatitis has occurred after one or two doses. In contrast, rifaximin is a course-based therapy whose IBS-D dose is different from its traveler’s diarrhea dose. Assess whether pain, urgency or whole-syndrome improvement is the actual treatment target (Allergan, Inc., 2024; Salix Pharmaceuticals, Inc., 2024; Salix Pharmaceuticals, Inc., 2025; Lembo et al., 2022).

Monitoring and Nonresponse

• Track abdominal pain, stool form/frequency, urgency, bloating and patient-defined function using a brief baseline and reassessment interval.
• Reassess the working diagnosis when new blood, weight loss, anemia, fever, severe persistent pain or nocturnal symptoms appear.
• Differentiate medication-related diarrhea from IBS-D after initiating secretagogues; evaluate hydration, especially in frail patients.
• Review anticholinergic burden, QT-related risk, interactions and pregnancy when adding antispasmodics or neuromodulators.
• Document the dietary trial, adequacy of fiber, and the patient’s response; avoid serial medications without assessing adherence and a treatable alternative cause.

Clinical discrimination: A patient whose PEG produces daily stools but leaves disabling pain has not necessarily achieved adequate IBS-C control. Conversely, a patient whose loperamide reduces diarrhea but leaves persistent urgency, bloating, or pain may need a different mechanism and reassessment. Drug success is measured across the symptomatic syndrome, not by stool count alone (Chang et al., 2022; Lembo et al., 2022).

IBS-M and IBS-U: Treat the Present Phenotype Without Overmedicating

Rome V recognizes recurrent, noncontinuous abdominal pain or discomfort on average at least three days per month during the preceding three months, associated with at least two of: defecation, a change in stool frequency, or a change in stool form. Symptoms must have begun at least six months before diagnosis. In contrast, Rome IV required abdominal pain on average at least one day per week and did not include discomfort. IBS-M includes both hard and loose stool episodes; IBS-U does not meet the stool-form threshold for a predominant subtype. Apply stool-form percentages to days with abnormal bowel movements rather than all stools. A positive clinical diagnosis remains appropriate when the pattern is compatible and focused assessment addresses alarm features or alternative explanations (Rome Foundation, 2026; Poole, 2026).

For IBS-M, identify whether pain, constipation, diarrhea, or bloating is disabling at the current visit. Consider a cautious soluble-fiber trial while tracking changes in stool pattern, abdominal discomfort, and pain; select any additional medication only for the currently predominant symptoms. A fixed daily antimotility agent may aggravate constipation; escalating laxatives without recognizing intermittent diarrhea may amplify variability. IBS-U needs individualized symptom treatment and reclassification only when longitudinal stool history supports it. These phenotypes are not indications to combine IBS-C secretagogues with IBS-D medicines automatically (Poole, 2026; Chey et al., 2022).

Pain, Bloating, and Brain–Gut Treatment Are Distinct Targets

In IBS-C, PEG can increase bowel movements while leaving visceral pain unchanged. In IBS-D, loperamide may reduce diarrhea and improve stool consistency, but evidence of benefit for urgency or global IBS symptoms is limited. For pain-predominant or persistent global symptoms, a low-dose tricyclic antidepressant may be considered after reviewing baseline constipation, comorbidities, interacting medicines, and drug-specific precautions (including QT or pregnancy risk when applicable); a TCA is a neuromodulator here, not a declaration that symptoms are psychological (Lembo et al., 2022).

Offer a time-limited, dietitian-supported low-FODMAP elimination followed by structured reintroduction when food-related symptoms are prominent. Avoid indefinite restriction and assess nutritional risk or disordered eating. Gut-directed cognitive behavioral therapy or hypnotherapy is a valid evidence-based adjunct when symptoms persist, functional impact is substantial, or the patient prefers a nonpharmacologic approach. These interventions can be used alongside appropriate medication rather than being reserved for treatment failure (Chey et al., 2022; Lacy et al., 2021).

A Response-Based Treatment Ladder

At baseline record the patient’s two or three most important outcomes: pain days or pain intensity, urgency/incontinence, spontaneous complete bowel movements, bloating and interference with work or sleep. Review a defined therapeutic trial for adherence, tolerability, and improvement in those outcomes, rather than escalating automatically. A drug that produces stool changes but not meaningful function or pain improvement may not meet the agreed target. When symptoms become nocturnal, bloody, progressive, or accompanied by anemia/weight loss, reopen the differential rather than labeling a new process refractory IBS (Chang et al., 2022; Lembo et al., 2022).

Decision pathway: Clinical decision

Clinical decision	Likely strategy	When it is inadequate or unsafe
IBS-M with alternating hard and loose stools	Assess the current predominant bowel pattern and pain burden; consider soluble fiber and monitor response before adding symptom-directed therapy.	Do not simultaneously prescribe chronic high-dose laxative and antimotility regimens without a documented target.
IBS-C: stools improve, pain persists	Review whether the chosen IBS-C therapy has evidence for global symptom relief, not stool frequency alone; consider behavioral treatment according to patient preference and availability.	Daily stools are not equivalent to remission of IBS pain.
IBS-D: urgency improves, global burden persists	Reassess diet and triggers, and consider an evidence-supported global therapy or a neuromodulator.	If alarm features or an atypical course emerge, reassess for inflammatory or infectious conditions; check the selected therapy’s contraindications, including eluxadoline exclusions.
Any subtype with new alarm features	Stop treating reflexively as IBS; evaluate alternative structural, inflammatory or malignant causes.	Bleeding, anemia, unintentional weight loss, fever and significant nocturnal symptoms are reassessment triggers.

Applied Clinical Case and Prescribing Rationale

Scenario: A 37-year-old with alternating 3–4-day periods of hard stools and loose urgency uses loperamide daily and reports increasing bloating and missed shifts. Hemoglobin is normal, but a medication history reveals frequent anticholinergic sleep-aid use. What changes?

Reasoned response: The appropriate next step is a longitudinal Bristol-stool and pain diary, review/removal of potentially constipating medicines, and a patient-defined target such as fewer severe pain days and fewer urgent episodes. Avoid automatically scheduling an antimotility drug in alternating constipation and diarrhea; prioritize a gradual soluble-fiber and dietitian-guided approach when appropriate. If disabling global symptoms remain, discuss a gut-directed behavioral intervention or phenotype-appropriate pharmacotherapy. New alarm features would change the diagnostic pathway, not simply justify a stronger IBS drug (Poole, 2026; Chang et al., 2022).

High-Yield Distinctions

Related YourDNP Resources

Pharmacology learning hub | Constipation Pharmacotherapy | Acute Diarrhea

---

---

References

Allergan, Inc. (2024, July). Viberzi (eluxadoline) tablets [U.S. prescribing information; current online label]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7821bd40-4c84-4984-951b-6436ae20421a

Allergan, Inc. (2026, May 21). Linzess (linaclotide) capsules [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09beda19-56d6-4a56-afdc-9a77b70b2ef3

Chang, L., Sultan, S., Lembo, A., Verne, G. N., Smalley, W., & Heidelbaugh, J. J. (2022). AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. Gastroenterology, 163(1), 118–136. https://doi.org/10.1053/j.gastro.2022.04.016

Chey, W. D., Hashash, J. G., Manning, L., & Chang, L. (2022). AGA clinical practice update on the role of diet in irritable bowel syndrome: Expert review. Gastroenterology, 162(6), 1737–1745.e5. https://doi.org/10.1053/j.gastro.2021.12.248

Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021). ACG clinical guideline: Management of irritable bowel syndrome. American Journal of Gastroenterology, 116(1), 17–44. https://doi.org/10.14309/ajg.0000000000001036

Legacy Pharma USA Inc. (2026, March 23). Lotronex (alosetron hydrochloride) tablets [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c216e967-436f-475a-8e6a-2ad11adc63af

Lembo, A., Sultan, S., Chang, L., Heidelbaugh, J. J., Smalley, W., & Verne, G. N. (2022). AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology, 163(1), 137–151. https://doi.org/10.1053/j.gastro.2022.04.017

Poole, T. M. (2026). Functional gastrointestinal disorders. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 22). McGraw Hill.

Rome Foundation. (2026). Rome V criteria. https://theromefoundation.org/rome-v-criteria/

Salix Pharmaceuticals, Inc. (2024, April 4). Trulance (plecanatide) tablets [U.S. prescribing information; current online label]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe2895bf-71a6-493a-b0ca-e06b2dfefc82

Salix Pharmaceuticals, Inc. (2025, June 25). Xifaxan (rifaximin) tablets [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1